CN106119385A - 一种诊断2型糖尿病的miRNA分子标志物hsa‑miR‑149‑3p及其应用 - Google Patents
一种诊断2型糖尿病的miRNA分子标志物hsa‑miR‑149‑3p及其应用 Download PDFInfo
- Publication number
- CN106119385A CN106119385A CN201610655996.9A CN201610655996A CN106119385A CN 106119385 A CN106119385 A CN 106119385A CN 201610655996 A CN201610655996 A CN 201610655996A CN 106119385 A CN106119385 A CN 106119385A
- Authority
- CN
- China
- Prior art keywords
- mir
- mirna
- mirna molecule
- molecule mark
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091069090 Homo sapiens miR-149 stem-loop Proteins 0.000 title claims abstract description 29
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 22
- 108091070501 miRNA Proteins 0.000 title claims abstract description 19
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 20
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 19
- 238000003753 real-time PCR Methods 0.000 claims abstract description 10
- 239000002299 complementary DNA Substances 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002679 microRNA Substances 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims description 15
- 238000010839 reverse transcription Methods 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 238000007689 inspection Methods 0.000 abstract description 4
- 210000005259 peripheral blood Anatomy 0.000 abstract description 3
- 239000011886 peripheral blood Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000000472 traumatic effect Effects 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 239000003550 marker Substances 0.000 abstract description 2
- 108700011259 MicroRNAs Proteins 0.000 description 28
- 239000000523 sample Substances 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 108091047577 miR-149 stem-loop Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于生物医药领域，涉及一种诊断2型糖尿病的miRNA分子标志物及其应用。步骤如下：血液总RNA的抽提及cDNA的制备；荧光定量PCR检测hsa‑miR‑149‑3p水平；miRNA分子标志物的评估。本发明通过大样本检测，发现新的外周血miRNA标志物hsa‑miR‑149‑3p在2型糖尿病患者中明显升高，且其分子水平与受检者血糖水平呈显著正相关。该检测方法操作简便，对受检者的创伤性小，且灵敏度高，特异性强，可用于早期和不同阶段2型糖尿病的诊断。在此基础上，本发明开发了检测血液hsa‑miR‑149‑3p的引物、试剂盒和检测方法，具有明显的临床应用价值。
Description
技术领域
本发明属于生物医药领域，涉及一种诊断2型糖尿病的miRNA分子标志物及其应用。
背景技术
糖尿病是一种以高血糖为主要特征的慢性代谢性疾病，持续性的高血糖引起的并发症会严重损害患者的生命健康。国际糖尿病联盟最新数据显示，2015年全球糖尿病成人患病人数已将近4亿人，而我国患病比例占据1/4左右，给社会和家庭带来日益沉重的负担。糖尿病按照发病机制主要分为1型和2型糖尿病。2型糖尿病也称为成人发病型糖尿病，占糖尿病比例的94％左右。2型糖尿病尚不能完全治愈，且在早期无明显的临床症状，病人常在体检或出现典型的症状才被确诊。如果在糖尿病前期能够及时发现并通过改变生活方式或药物干预即可防止并发症的出现。目前2型糖尿病的临床诊断指标主要包括：空腹血糖(FBG)、葡萄糖耐量试验(OGTT)、糖化血红蛋白(GHb)等，但这些指标多用于罹患糖尿病的诊断及分型，无法进行糖尿病的早期诊断。
microRNA(miRNA)是一类高度保守的非编码小RNA，长度约为18-25个核苷酸。miRNA广泛存在于原核和真核生物体内，对细胞的增殖、分化、凋亡，胚胎的发育，器官的形成，内分泌的调控，疾病的发生、发展都起着重要的调节作用。miRNA通过靶向一个或多个基因的3’非编码区域，降解其mRNA或抑制其翻译的进行，从而达到对基因表达的调控作用。miRNA与肿瘤、心脑血管疾病、内分泌疾病等诸多疾病的发生密切相关。目前已有大量的研究表明miRNA从胰岛发育、胰岛细胞的凋亡、胰岛素的生成、分泌以及胰岛素作用等各个阶段参与糖尿病的发病，但研究手段多局限于动物模型或患病组织，且需要通过创伤性的方式获取。
血液中存在着上千种miRNA，这些小分子RNA不仅含量丰富、性质稳定，便于检测，且与特异性疾病存在着显著的关联性。血液中的miRNA由组织分泌而得，分析血液中的miRNA可以间接反映组织中的miRNA水平。因此通过无创性的手段，快速、灵敏、特异性的定量检测方法，筛选2型糖尿病人血液中特异性表达或异常表达的循环miRNA作为分子标志物，研制糖尿病早期的辅助诊断试剂盒，用于监测2型糖尿病易感人群、评估罹患风险并采取有效的干预措施，对于遏制当前爆发性的糖尿病发病趋势具有显著的社会价值。
发明内容
本发明公开了一种用于诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p，提供了在制备2型糖尿病辅助诊断试剂盒中的应用。
为解决上述问题，本发明采用以下技术方法：
一种诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p的应用，步骤如下：
(1)血液总RNA的抽提及cDNA的制备；
(2)荧光定量PCR检测hsa-miR-149-3p水平；
(3)miRNA分子标志物的评估。
所述miRNA分子标志物hsa-miR-149-3p，其miRNA序列如SEQ ID NO：1所示，DNA序列如SEQ ID NO：2所示。
所述步骤(1)中cDNA的制备所用的反转录引物序列如SEQ ID NO：3所示。
所述步骤(2)实时荧光定量PCR检测根据染料法检测、探针法检测。
所述步骤(2)中荧光定量PCR的正向引物如SEQ ID NO：4所示、反向引物如SEQ IDNO：5所示。
诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p的正向引物和反向引物，在制备2型糖尿病辅助诊断试剂盒中的应用。
本发明的有益效果在于：
第一：本发明通过引入外源性miRNA作为参照基因，通过miRNA荧光定量PCR检测外周血中hsa-miR-149-3p水平；相对于传统的使用内源性血清miRNA作为参照基因进行检测的方法，避免了个体间内参miRNA差异造成的数据偏差，显著提高了检测结果的稳定性。
第二：本发明通过大样本检测，发现新的外周血miRNA标志物hsa-miR-149-3p在2型糖尿病患者中明显升高，且其分子水平与受检者血糖水平呈显著正相关；该检测方法操作简便，对受检者的创伤性小，且灵敏度高，特异性强，可用于早期和不同阶段2型糖尿病的诊断。在此基础上，本发明开发了检测血液hsa-miR-149-3p的引物、试剂盒和检测方法，具有明显的临床应用价值。
附图说明
图1为2型糖尿病病例组和健康对照组中hsa-miRNA-149-3p的表达水平示意图。
图2为检测样本中hsa-miRNA-149-3p水平与空腹血糖水平的相关性分析示意图。
具体实施方式
以下通过实施例进一步描述本发明，其中包括使用材料及具体来源。但应当理解的是，这些只是示例性的，而非限制本发明。与如下试剂、仪器的类型及型号，或性质或功能相似或相同的材料均可以用于本发明的实施。除非另有所指，本发明中用到的试剂可以是任何合适的市售试剂。
下述示例中的方法如无特殊说明均为普通方法。
主要材料：
1.临床样品的采集
发明人于2015年开始至今从河南大学附属淮河医院收集了大量的2型糖尿病人和正常体检人群的外周血样品。整个收集及后续实验过程符合医学伦理道德要求并严格遵循病例资料的保密原则。研究样品的采样、分装、保存条件一致。通过对病历资料的整理，发明人选择了25例符合下列标准的样品作为实时荧光定量PCR检测的实验样品。
空腹血液血糖在3.9-6.1mmol/L之间的健康人群定义为健康对照组；
空腹血液血糖大于或等于7.0mmol/L，连续两次重复测定结果相近，由内分泌医生确诊为2型糖尿病，且未经任何药物治疗的人群定义为病例组。
2.血液中总RNA的抽提
每200μL新鲜的血液样品，加入1μL，1μM的miRNA检测外参(Tiangen)，混匀后再加入600μL Tri reagent，漩涡震荡充分裂解血细胞，室温下静置5分钟后，加入1/10倍Trireagen体积的的BCP溶液，涡旋混匀15秒后室温静置10分钟。4℃，13400g室温离心15分钟；将上清液转移至新的1.5mL离心管，加入等倍上清体积的异丙醇，轻轻颠倒混匀数次后，-80℃条件下静置1小时，4℃，13400g离心1小时后，吸除上清，加入500μL无RNA酶水新鲜配制的75％乙醇溶液，轻吹悬浮清洗RNA，4℃，13400g离心5分钟沉淀RNA。吸除上清后，置于室温通风处晾干，干燥5分钟左右。加入适量无核酸酶水并置于55℃水浴10分钟，待充分溶解后测定OD260和OD280吸收值。一般认为A260/A280在1.8-2.1之间可以初步判定总RNA质量较好。
3.荧光定量PCR检测hsa-miR-149-3p水平
取2μg总RNA作为模板，使用针对miRNA的cDNA第一链合成试剂盒(BioTeke)对miRNA进行加Poly(A)尾反应，反应结束后配制反转录体系：
37℃反应60分钟，反转录成cDNA。将cDNA稀释至4ng/μL作为荧光定量PCR反应的模板。使用针对hsa-miR-149-3p、外参基因的正向引物，通用反向引物及2×SYBR Green qPCRMixture，在ABI 7500荧光定量PCR仪上进行扩增。
miRNA的反转录引物如SEQ ID NO：3所示、正向引物如SEQ ID NO：4所示和通用反向引物如SEQ ID NO：5所示。
本发明提供的检测血液miRNA的引物组合基于poly(A)聚合酶加尾法设计而得。在一些具体的实施方式中，所述的实时荧光定量PCR检测hsa-miRNA-149-3p的引物也可以根据茎环方法设计而得，并不局限于其设计原理。反应体系如下：
外参基因体系为：
hsa-miR-149-3p体系为：
PCR条件为：50℃20秒；95℃10分钟；95℃1分钟；60℃1分钟，重复40个循环；测得样品miR-149-3p扩增的CT值，以外参基因扩增的CT值进行标准化校正。
4.数据处理与分析
两组血液样品miRNA表达量的比值使用2-ΔΔCT法进行计算，其中ΔΔCT＝[CT1(miRNA)-CT1(外参)]-[CT2(miRNA)-CT2(外参)]，CT miRNA是样品miR-149-3p 扩增的CT值，CT外参是样品外参基因扩增的CT值，CT1是病例组或健康对照组样品扩增的CT值，CT2是一例健康对照组样品扩增的CT值。具体结果如下表所示：
表1.荧光定量PCR检测健对照组和病例组血液中hsa-miR-149-3p的表达水平
| 样品编号 | 2型糖尿病 | hsa-miR-149-3p相对表达水平 |
| 1 | 0 | 1.324 |
| 2 | 0 | 0.814 |
| 3 | 0 | 1.389 |
| 4 | 0 | 1.104 |
| 5 | 0 | 0.595 |
| 6 | 0 | 0.463 |
| 7 | 0 | 1.520 |
| 8 | 0 | 0.818 |
| 9 | 0 | 0.973 |
| 10 | 1 | 2.469 |
| 11 | 1 | 2.265 |
| 12 | 1 | 1.027 |
| 13 | 1 | 1.737 |
| 14 | 1 | 1.812 |
| 15 | 1 | 1.533 |
| 16 | 1 | 1.557 |
| 17 | 1 | 1.416 |
| 18 | 1 | 2.574 |
| 19 | 1 | 1.178 |
| 20 | 1 | 1.224 |
| 21 | 1 | 2.915 |
| 22 | 1 | 1.480 |
| 23 | 1 | 1.750 |
| 24 | 1 | 1.292 |
表1中，“0”表示健康人群，“1”表示2型糖尿病患者。
经SPSS软件进行统计分析，hsa-miR-149-3p在2型糖尿病病例组和健康对照组中的表达水平具有显著差异(P＝0.002)，且hsa-miR-149-3p水平与空腹血糖水平呈明显正相关(R＝0.62，P＝0.001)，结果如图1所示。P<0.05认为具有统计学意义。
由此可以确定，hsa-miR-149-3p在2型糖尿病患者的血液中明显升高，可以作为2型糖尿 病的检测分子标志物。
Claims (6)
1.一种诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p的应用，其特征在于：步骤如下：
（1）血液总RNA的抽提及cDNA的制备；
（2）荧光定量PCR检测hsa-miR-149-3p水平；
（3）miRNA分子标志物的评估。
2.如权利要求1所述的诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p，其特征在于：所述miRNA分子标志物hsa-miR-149-3p，其miRNA序列如SEQ ID NO：1所示，DNA序列如SEQ ID NO：2所示。
3.如权利要求1所述的诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p的应用，其特征在于：所述步骤（1）中cDNA的制备所用的反转录引物序列如SEQ ID NO：3所示。
4.如权利要求1所述的诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p的应用，其特征在于：所述步骤（2）实时荧光定量PCR检测根据染料法检测、探针法检测。
5.如权利要求1所述的诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p的应用，其特征在于：所述步骤（2）中荧光定量PCR的正向引物如SEQ ID NO：4所示、反向引物如SEQ IDNO：5所示。
6.如权利要求5所述的诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p的正向引物和反向引物，在制备2型糖尿病辅助诊断试剂盒中的应用。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610655996.9A CN106119385B (zh) | 2016-08-11 | 2016-08-11 | 一种诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p及其应用 |
| PCT/CN2017/081994 WO2018028249A1 (zh) | 2016-08-11 | 2017-04-26 | 一种miRNA及其在治疗代谢性疾病中的应用 |
| US16/264,585 US20190153446A1 (en) | 2016-08-11 | 2019-01-31 | Mir-149-3p and method for treating metabolic disease using the same |
| US17/823,076 US20230088599A1 (en) | 2016-08-11 | 2022-08-29 | Mir-149-3p and method for treating metabolic disease using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610655996.9A CN106119385B (zh) | 2016-08-11 | 2016-08-11 | 一种诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106119385A true CN106119385A (zh) | 2016-11-16 |
| CN106119385B CN106119385B (zh) | 2019-03-05 |
Family
ID=57258874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610655996.9A Active CN106119385B (zh) | 2016-08-11 | 2016-08-11 | 一种诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p及其应用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20190153446A1 (zh) |
| CN (1) | CN106119385B (zh) |
| WO (1) | WO2018028249A1 (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375317A (zh) * | 2017-06-28 | 2017-11-24 | 河南大学 | miR‑149‑3p及其拟似物在制备防治肥胖、动脉粥样硬化、高血脂的药物中的应用 |
| WO2018028249A1 (zh) * | 2016-08-11 | 2018-02-15 | 河南大学 | 一种miRNA及其在治疗代谢性疾病中的应用 |
| CN109852688A (zh) * | 2019-04-02 | 2019-06-07 | 中国药科大学 | 一种2型糖尿病的诊断引物及试剂盒、以及非编码rna分子标志物的应用 |
| CN111826433A (zh) * | 2019-04-23 | 2020-10-27 | 清华大学深圳研究生院 | 一种LncRNA在糖尿病预后评估和反复流产预警中的应用 |
| CN114634977A (zh) * | 2020-12-15 | 2022-06-17 | 南京大学 | 与2型糖尿病胰岛β细胞受损表型相关的血清/血浆miRNA组合标志物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102080083A (zh) * | 2009-12-01 | 2011-06-01 | 中国科学院上海药物研究所 | 人miR-149反义核酸及其应用 |
| CN104630224A (zh) * | 2015-01-08 | 2015-05-20 | 江苏大学 | 与BafilomycinA1抑制肝癌和卵巢癌细胞系相关的一组microRNA |
| CN105483230A (zh) * | 2015-12-23 | 2016-04-13 | 宁波大学 | 用于检测2型糖尿病视网膜病变的miR-3197分子标记物及其扩增引物和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011068869A1 (en) * | 2009-12-01 | 2011-06-09 | Abraxis Bioscience, Llc | 17-AAG POTENTIATING MicroRNAs |
| CN102250904B (zh) * | 2011-07-13 | 2013-11-13 | 中国科学技术大学 | 一种预防和/或治疗黑色素瘤的药物 |
| CN103555724B (zh) * | 2013-10-24 | 2015-08-05 | 浙江理工大学 | 2型糖尿病的血清miRNA生物标志物及其应用 |
| CN106119385B (zh) * | 2016-08-11 | 2019-03-05 | 河南大学 | 一种诊断2型糖尿病的miRNA分子标志物hsa-miR-149-3p及其应用 |
-
2016
- 2016-08-11 CN CN201610655996.9A patent/CN106119385B/zh active Active
-
2017
- 2017-04-26 WO PCT/CN2017/081994 patent/WO2018028249A1/zh active Application Filing
-
2019
- 2019-01-31 US US16/264,585 patent/US20190153446A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102080083A (zh) * | 2009-12-01 | 2011-06-01 | 中国科学院上海药物研究所 | 人miR-149反义核酸及其应用 |
| CN104630224A (zh) * | 2015-01-08 | 2015-05-20 | 江苏大学 | 与BafilomycinA1抑制肝癌和卵巢癌细胞系相关的一组microRNA |
| CN105483230A (zh) * | 2015-12-23 | 2016-04-13 | 宁波大学 | 用于检测2型糖尿病视网膜病变的miR-3197分子标记物及其扩增引物和应用 |
Non-Patent Citations (2)
| Title |
|---|
| BURACZYNSKA M，ET AL: "Polymorphism in microRNA-196a2 contributes to the risk of cardiovascular disease in type 2 diabetes patients", 《JOURNAL OF DIABETES AND ITS COMPLICATIONS》 * |
| GOMES CLARISSA P. C. ET AL: "The implications on clinical diagnostics of using microRNA-based biomarkers in exercise", 《EXPERT REVIEWS OF MOLECULAR DIAGNOSTICS》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018028249A1 (zh) * | 2016-08-11 | 2018-02-15 | 河南大学 | 一种miRNA及其在治疗代谢性疾病中的应用 |
| CN107375317A (zh) * | 2017-06-28 | 2017-11-24 | 河南大学 | miR‑149‑3p及其拟似物在制备防治肥胖、动脉粥样硬化、高血脂的药物中的应用 |
| CN107375317B (zh) * | 2017-06-28 | 2020-09-04 | 河南大学 | miR-149-3p及其拟似物在制备防治肥胖、动脉粥样硬化、高血脂的药物中的应用 |
| CN109852688A (zh) * | 2019-04-02 | 2019-06-07 | 中国药科大学 | 一种2型糖尿病的诊断引物及试剂盒、以及非编码rna分子标志物的应用 |
| CN109852688B (zh) * | 2019-04-02 | 2021-03-16 | 中国药科大学 | 一种2型糖尿病的诊断引物及试剂盒、以及非编码rna分子标志物的应用 |
| CN111826433A (zh) * | 2019-04-23 | 2020-10-27 | 清华大学深圳研究生院 | 一种LncRNA在糖尿病预后评估和反复流产预警中的应用 |
| CN111826433B (zh) * | 2019-04-23 | 2023-08-18 | 清华大学深圳研究生院 | 一种LncRNA在糖尿病预后评估和反复流产预警中的应用 |
| CN114634977A (zh) * | 2020-12-15 | 2022-06-17 | 南京大学 | 与2型糖尿病胰岛β细胞受损表型相关的血清/血浆miRNA组合标志物及其应用 |
| CN114634977B (zh) * | 2020-12-15 | 2024-04-09 | 南京大学 | 与2型糖尿病胰岛β细胞受损表型相关的血清/血浆miRNA组合标志物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190153446A1 (en) | 2019-05-23 |
| CN106119385B (zh) | 2019-03-05 |
| WO2018028249A1 (zh) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106119385A (zh) | 一种诊断2型糖尿病的miRNA分子标志物hsa‑miR‑149‑3p及其应用 | |
| CN103555724B (zh) | 2型糖尿病的血清miRNA生物标志物及其应用 | |
| CN106148537B (zh) | 一种与2型糖尿病相关的血清或血浆miRNA标志物及其应用 | |
| CN106434872A (zh) | 一种诊断2型糖尿病的miRNA分子标志物hsa‑miR‑152‑3p及其应用 | |
| CN105039530B (zh) | 线粒体相关精浆微小核糖核酸作为人类严重弱精子症发生的标志物及其应用 | |
| CN109609633A (zh) | 一种与乳腺癌辅助诊断相关的血清miRNA标志物及其应用 | |
| CN103805696A (zh) | 一种诊断类风湿关节炎的microRNA分子标志物及其检测试剂盒 | |
| CN108079317A (zh) | 口服活性受体激活剂治疗肥胖相关疾病方法与系统 | |
| CN110423811A (zh) | 脓毒症诊断标志物 | |
| CN107557472B (zh) | 胶质瘤诊断标志物circ9:135881633|135883078及应用 | |
| CN107937532B (zh) | 胶质瘤诊断标志物hsa_circ_0021827及应用 | |
| CN109223818A (zh) | miR-3158-3p在制备诊断、预防和/或治疗特应性皮炎产品中的应用 | |
| CN104962654A (zh) | lncRNA-MALAT1在制备增生性玻璃体视网膜病变诊断试剂中的应用 | |
| CN109593852B (zh) | 一种与鼻咽癌辅助诊断相关的血清miRNA标志物及其应用 | |
| CN109536612B (zh) | 一种与鼻咽癌辅助诊断相关的血浆miRNA标志物及其应用 | |
| Sarookhani et al. | Plasma miR-135a; a potential biomarker for diagnosis of new type 2 diabetes (T2DM) | |
| CN108796063A (zh) | Micro-15b在制备诊断糖尿病视网膜病变试剂中的应用 | |
| CN116103387A (zh) | 一种检测高度近视并发脉络膜新生血管病变生物标记物、检测试剂盒及应用 | |
| Ezzat et al. | Expression of micro RNA192 in type 2 diabetes mellitus relation to glycemic control, metabolic abnormalities, renal and ocular complications | |
| CN111560427A (zh) | lncRNA作为新生儿肠外营养相关性肝病特异性标志物的应用 | |
| CN107523641B (zh) | 血清miRNAs生物标志物及其应用 | |
| CN109706244A (zh) | 检测microRNA表达水平的肝癌诊断试剂盒及其应用 | |
| CN117106919B (zh) | 外泌体miRNA组合在早期肺癌检测中的应用 | |
| Moustafa et al. | Circulating Angiogenic microRNA-27b and Thrombospondin-1 (TSP-1) Level in Patients with Diabetic Retinopathy | |
| CN103757017B (zh) | 一种与人类胎儿生长受限发生相关的血清微小核糖核酸标志物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |